Biopharmaceutical major Biocon is on a high. It recently rolled out insulin Glargine at the lowest market price in the US which opens up a $2.2 billion opportunity for the R&D focused company.
While Biocon has entered over 40 countries with its two offerings in the insulin portfolio namely recombinant human insulin (rh-insulin) and insulin Glargine, the Bengaluru-based company is aiming to reach one in five diabetes patients in need of insulin-based therapy around the globe. “A blockbuster is not earning $1 billion in revenue but touching the lives of 1 billion patients. We ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
Copyrights © 2020 Business Standard Private Ltd. All rights reserved.
